

## PRODUCT MONOGRAPH

### **PrDALACIN® C FLAVOURED GRANULES**

Clindamycin Palmitate Hydrochloride  
For Oral Solution, USP  
75 mg/5 mL clindamycin when reconstituted

Antibiotic

Pfizer Canada ULC  
17,300 Trans-Canada Highway  
Kirkland, Quebec H9J 2M5

Date of Revision:  
12 August 2019

Submission Control No: 220071

® Pfizer Enterprises, SARL  
Pfizer Canada ULC, Licensee  
© Pfizer Canada ULC 2019

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	7
DRUG INTERACTIONS .....	9
DOSAGE AND ADMINISTRATION.....	11
OVERDOSAGE .....	13
ACTION AND CLINICAL PHARMACOLOGY .....	13
STORAGE AND STABILITY.....	15
SPECIAL HANDLING INSTRUCTIONS .....	15
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	15
<b>PART II: SCIENTIFIC INFORMATION</b> .....	<b>16</b>
PHARMACEUTICAL INFORMATION.....	16
CLINICAL TRIALS.....	17
DETAILED PHARMACOLOGY .....	17
MICROBIOLOGY .....	17
TOXICOLOGY .....	24
REFERENCES .....	27
<b>PART III: PATIENT MEDICATION INFORMATION</b> .....	<b>29</b>

# PrDALACIN<sup>®</sup> C FLAVOURED GRANULES

Clindamycin Palmitate Hydrochloride

## PART I: HEALTH PROFESSIONAL INFORMATION

### SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Oral Solution, 75 mg/5 mL clindamycin, when reconstituted	Sucrose: when reconstituted with 75 mL of water, each 5 mL contains approximately 1837 mg of sucrose <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

### INDICATIONS AND CLINICAL USE

DALACIN C FLAVOURED GRANULES (clindamycin palmitate hydrochloride) is indicated in the treatment of serious infections due to sensitive anaerobic bacteria, such as *Bacteroides* species, *Peptostreptococcus*, anaerobic streptococci, *Clostridium* species and microaerophilic streptococci.

DALACIN C FLAVOURED GRANULES is also indicated in serious infections due to sensitive gram-positive aerobic organisms (staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when the patient is intolerant of, or the organism is resistant to other appropriate antibiotics.

DALACIN C FLAVOURED GRANULES is indicated for prophylaxis against alpha-hemolytic (viridans group) streptococci before dental, oral and upper respiratory tract surgery.

- a) The prophylaxis of bacterial endocarditis in patients allergic to penicillin with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular dysfunction, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without regurgitation but associated with thickening and/or redundancy of the valve leaflets.
- b) Patients taking oral penicillin for prevention or recurrence of rheumatic fever should be given another agent such as clindamycin, for prevention of bacterial endocarditis.

**Geriatrics (> 65 years of age):**

Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients.

**Pediatrics (over one month of age):**

It is not known if use of clindamycin in the pediatric population is associated with differences in safety or effectiveness compared with adult patients.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALACIN C FLAVOURED GRANULES and other antibacterial drugs, DALACIN C FLAVOURED GRANULES should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

**CONTRAINDICATIONS**

DALACIN C FLAVOURED GRANULES (clindamycin palmitate hydrochloride) is contraindicated in patients with a known hypersensitivity to clindamycin or lincomycin or to any component of the formulation or component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the product monograph.

Until further clinical experience is obtained DALACIN C FLAVOURED GRANULES is not indicated in the newborn (infant below 30 days of age).

**WARNINGS AND PRECAUTIONS****General**

In patients with G-6-PD deficiency, the combination of clindamycin with primaquine may cause hemolytic reactions. Routine blood examinations should be done during therapy with primaquine to monitor potential hematologic toxicities. Reference should also be made to the primaquine product monograph for other possible risk groups for other hematologic reactions (see **ADVERSE REACTIONS**).

DALACIN C FLAVOURED GRANULES (clindamycin palmitate hydrochloride) should be prescribed with caution in atopic individuals.

DALACIN C FLAVOURED GRANULES do not diffuse adequately into cerebrospinal fluid and thus should not be used in the treatment of meningitis.

The use of antibiotics occasionally results in overgrowth of non-susceptible organisms - particularly yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the clinical situation.

Care should be exercised when treating patients with multiple medications (see **DRUG INTERACTIONS**).

### **Gastrointestinal**

DALACIN C FLAVOURED GRANULES should be prescribed with caution in patients with a history of gastrointestinal disease, particularly colitis, inflammatory bowel disease (including regional enteritis and ulcerative colitis), or a history of antibiotic-associated colitis (including pseudomembranous colitis).

### ***Clostridium difficile*-associated disease (CDAD)**

*Clostridium difficile*-associated disease (CDAD) has been reported with use of many antibacterial agents, including DALACIN C FLAVOURED GRANULES (clindamycin palmitate hydrochloride). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *C. difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases (see **ADVERSE REACTIONS**).

### **Hepatic/Biliary/Pancreatic**

In patients with moderate to severe liver disease, prolongation of the half-life of clindamycin has been found. However, it was postulated from studies that when given every eight hours, accumulation of clindamycin should rarely occur. Therefore, dosage reduction in liver disease is not generally considered necessary. Periodic liver enzyme determinations should be made when treating patients with severe liver disease.

### **Immune**

Serious hypersensitivity reactions, including anaphylactoid reactions, severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), and dermatological reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients on clindamycin therapy. If a hypersensitivity reaction occurs clindamycin should be discontinued and appropriate therapy should be initiated (see **CONTRAINDICATIONS, ADVERSE REACTIONS**).

## **Renal**

DALACIN C FLAVOURED GRANULES dose modification may not be necessary in patients with renal disease. The serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function.

## **Susceptibility/Resistance**

### **Development of drug-resistant bacteria**

Prescribing DALACIN C FLAVOURED GRANULES in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

## **Special Populations**

### **Pregnant Women:**

There are no adequate and well-controlled studies in pregnant women. Safety for use in pregnancy has not been established.

Clindamycin should not be used in pregnancy unless clearly needed and unless the expected benefits to the mother outweigh any potential risks to the fetus.

Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal blood concentrations. Clindamycin was widely distributed in fetal tissues with the highest concentration found in liver.

Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 20 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin except at doses that caused maternal toxicity. In one mouse strain, cleft palates were observed in treated fetuses; this response was not produced in other mouse strains or in other species, and therefore may be a strain specific effect. Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the fetus due to clindamycin, except at doses that caused maternal toxicity. Animal reproduction studies are not always predictive of human response.

### **Nursing Women:**

Clindamycin has been reported to appear in human breast milk in ranges from <0.5 to 3.8 mcg/mL.

Clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora such as diarrhea or blood in the stool, or rash. Because of the potential for serious adverse reactions in nursing infants, if clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. If DALACIN C FLAVOURED GRANULES is used by a nursing mother, monitor the infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or blood in the stool indicating possible antibiotic-associated colitis.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DALACIN C FLAVOURED GRANULES and any potential adverse

effects on the breastfed child from DALACIN C FLAVOURED GRANULES or from the underlying maternal condition.

**Geriatrics (> 60 years of age):**

Experience has demonstrated that antibiotic-associated colitis may occur more frequently and with increased severity among elderly (> 60 years) and debilitated patients. These patients should be carefully monitored for the development of diarrhea.

**Pediatrics (over one month of age):**

When DALACIN C FLAVOURED GRANULES is administered to the pediatric population, appropriate monitoring of organ system functions is desirable.

**Monitoring and Laboratory Tests**

Periodic liver and kidney function tests and blood counts should be performed during prolonged therapy when treating patients with severe liver disease.

When DALACIN C FLAVOURED GRANULES is administered to the pediatric population, appropriate monitoring of organ system functions is desirable.

As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.

**ADVERSE REACTIONS**

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

Adverse drug reaction frequencies for the three clindamycin formulations (clindamycin capsules, clindamycin granules for oral solution and clindamycin injection) are based on the clinical data sources from the original drug submission and on the total number of patients enrolled in the clinical trials (N=1787).

Adverse drug reactions that were considered causally related to clindamycin and observed in  $\geq$  1% of patients are presented below in Table 1. They are listed according to MedDRA system organ class.

**Table 1. Adverse Drug Reactions Occurring in  $\geq 1\%$  of Patients treated with clindamycin within the Original Clinical Trials**

<b>Adverse Reaction</b> System Organ Class / Preferred Term	<b>clindamycin</b> Total N=1787 <sup>1</sup> n (%)
<b>Gastrointestinal disorders</b>	
Diarrhea	26 (1.45)
<b>Investigations</b>	
Liver function test abnormal	66 (3.7)
<b>Skin and subcutaneous tissue disorders</b>	
Rash maculopapular	21 (1.18)

<sup>1</sup>clindamycin hydrochloride capsules N=851; clindamycin granules for oral solution N=340; clindamycin phosphate injection N=596

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

Less common adverse drug reactions that were considered causally related to clindamycin and observed in < 1% of patients are listed below.

*Blood and lymphatic system disorders:* Eosinophilia.

*Gastrointestinal disorders:* Nausea, abdominal pain and vomiting.

*General disorders and administration site conditions:* Local irritation, pain, abscess formation have been seen with IM injection.

*Nervous system disorders:* Dysgeusia.

*Skin and subcutaneous tissue disorders:* Urticaria, erythema multiforme and pruritus.

**Post-Market Adverse Drug Reactions**

Additional adverse events which have been reported in temporal association with DALACIN C formulations (clindamycin capsules, clindamycin granules for oral solution and clindamycin injection) since market introduction are listed below. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be established.

*Blood and lymphatic system disorders:* Agranulocytosis, leucopenia, neutropenia and thrombocytopenia. In clindamycin/primaquine combination studies, serious hematologic toxicities (grade III, grade IV neutropenia or anemia, platelet counts < 50 x 10<sup>9</sup>/L, or methemoglobin levels of 15% or greater) have been observed.

*Cardiac disorders:* Cardio-respiratory arrest and hypotension have been seen with rapid intravenous administration.

*Gastrointestinal disorders:* Colitis and pseudomembranous colitis. *Clostridium difficile*-associated disease (CDAD) has been observed and may manifest as a range of symptoms varying from watery diarrhea to fatal colitis, the onset of which may occur during or after antibacterial treatment (see **WARNINGS AND PRECAUTIONS**). Esophagitis and esophageal ulcer have been reported with the oral formulations.

*General disorders and administration site conditions:* Injection site irritation and thrombophlebitis. These reactions can be minimized by deep IM injection and avoidance of indwelling intravenous catheters.

*Hepatobiliary disorders:* Jaundice.

*Immune system disorders:* Generalized mild to moderate morbilliform-like skin rashes, anaphylactic shock, anaphylactoid reactions, anaphylactic reactions, hypersensitivity, and drug reaction with eosinophilia and systemic symptoms (DRESS).

*Infections and infestations:* *Clostridium difficile* colitis.

*Musculoskeletal:* Polyarthrititis.

*Renal and urinary disorders:* Renal dysfunction as evidenced by azotemia, oliguria and/or proteinuria.

*Skin and subcutaneous tissue disorders:* Toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), erythema multiforme, dermatitis exfoliative, dermatitis bullous, dermatitis vesiculobullous, rash morbilliform, vaginal infection, vaginitis, acute generalized exanthematous pustulosis (AGEP), angioedema.

*Vascular disorders:* Thrombophlebitis has been seen with rapid intravenous administration.

## **DRUG INTERACTIONS**

### **Overview**

Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite, N-desmethylclindamycin. Therefore inhibitors of CYP3A4 and CYP3A5 may reduce clindamycin clearance and inducers of these isoenzymes may increase clindamycin clearance. In the presence of strong CYP3A4 inducers such as rifampin, monitor for loss of effectiveness.

*In vitro* studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1, or CYP2D6 and only moderately inhibits CYP3A4. Therefore, clinically important interactions between clindamycin and coadministered drugs metabolized by these CYP enzymes are unlikely.

Clindamycin has been shown to have neuromuscular blocking properties and potential antagonism with erythromycin and aminoglycosides (see **Table 2**).

In a clindamycin/primaquine combination study, serious hematologic toxicities have been observed, but the contribution of clindamycin, if any, is unknown (see **ADVERSE REACTIONS**).

### **Drug-Drug Interactions**

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction.

**Table 2 - Established or Potential Drug-Drug Interactions**

<b>Proper name</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
Neuromuscular blocking agents Examples include: atracurium, doxacurium, pancuronium, vecuronium	CS	Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.	Use with caution in patients receiving these agents concurrently.
aminoglycosides	T	Clindamycin is reported to antagonize bactericidal activity of aminoglycosides <i>in vitro</i> . <i>In vivo</i> antagonism has not been demonstrated.	
erythromycin	T	Antagonism has been demonstrated between clindamycin and erythromycin <i>in vitro</i> . Clindamycin and erythromycin may compete for the same protein binding site in bacteria.	Due to possible clinical significance the two drugs should not be administered concurrently.
Inhibitors of CYP3A4, CYP3A5	T	Clearance of clindamycin may be reduced.	
Inducers of CYP3A4, CYP3A5	T	Clearance of clindamycin may be increased.	Monitor for loss of effectiveness.

Strong inducers of CYP3A4 such as rifampin	CS and CT	Rifampin appears to dramatically decrease the serum clindamycin concentration.	Serum clindamycin levels and effectiveness should be carefully monitored. A clinically relevant effect of clindamycin on rifampin concentrations is not expected.
--	-----------	--	---

Legend: CS = Case Study; CT = Clinical Trial; T = Theoretical

### **Drug-Food Interactions**

Interactions with food have not been established.

### **Drug-Herb Interactions**

Efficacy of clindamycin should be closely monitored in patients using concomitant St-John's wort, a CYP3A4 inducer.

### **Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

DALACIN C FLAVOURED GRANULES dose modification may not be necessary in patients with renal disease. DALACIN C FLAVOURED GRANULES dosage reduction in liver disease is not generally considered necessary. Dosage adjustments are not necessary in the elderly with normal hepatic function and normal (age-adjusted) renal function.

### **Recommended Dose and Dosage Adjustment**

#### **Children (Over one month of age)**

One of the following three dosage ranges should be selected depending on the severity of the infection:

- 8 - 12 mg/kg/day (4-6 mg/lb/day) divided into 3 or 4 equal doses.
- 13 - 16 mg/kg/day (6.5-8.0 mg/lb/day) divided into 3 or 4 equal doses.
- 17 - 25 mg/kg/day (8.5-12.5 mg/lb/day) divided into 3 or 4 equal doses.

<b>Weight Pounds</b>	<b>8-12 mg/kg/day 4-6 mg/lb/day</b>	<b>13-16 mg/kg/day 6.5-8.0 mg/lb/day</b>	<b>17-25 mg/kg/day 8.5-12.5 mg/lb/day</b>
22-40	37.5 mg q. 6h.	75 mg q. 8h.	75 mg q. 6h.
40-55	75 mg q. 8h.	75 mg q. 6h.	150 mg q. 8h.
55-75	75 mg q. 6h.	150 mg q. 8h.	150 mg q. 6h.
75-100	150 mg q. 8h.	150 mg q. 6h.	300 mg q. 8h.
100 and over--use adult dosage	150 mg q. 6h.	300 mg q. 6h.	450 mg q. 6h.

Note: In cases of  $\beta$ -haemolytic streptococcal infections, treatment should continue for at least 10 days to diminish the likelihood of subsequent rheumatic fever or glomerulonephritis.

#### **For prevention of endocarditis**

**Adults:** 300 mg orally 1 hour before procedure; then 150 mg 6 hours after initial dose.

**Children:** 10 mg/kg (not to exceed adult dose) orally 1 hour before procedure; then 5 mg/kg 6 hours after initial dose.

#### **Missed Dose**

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. The dose should not be doubled to make up for a missed dose.

#### **Administration**

Absorption of clindamycin is not appreciably modified by ingestion of food and DALACIN C FLAVOURED GRANULES may be taken with meals.

#### **Reconstitution:**

100 mL Size - Reconstitute bottles of 100 mL with **75 mL** of water. Add a large portion of the water and shake vigorously; add the remainder of the water and shake until the solution is uniform.

When reconstituted with 75 mL demineralized or distilled water, each 5 mL (teaspoonful) contains clindamycin palmitate hydrochloride equivalent to 75 mg clindamycin base and the total solution volume is 100 mL.

## OVERDOSAGE

Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.

No cases of overdosage have been reported. It would be expected however, that should overdosage occur, gastrointestinal side effects including abdominal pain, nausea, vomiting and diarrhea might be seen. During clinical trials, one three year old child was given 100 mg/kg of clindamycin hydrochloride for five days and showed mild abdominal pain and diarrhea. One 13 year old patient was given 75 mg/kg of clindamycin hydrochloride for five days with no side effects. In both cases, laboratory values remained normal. In a study in normal adult volunteers up to 1800 mg/day for 21 days of clindamycin palmitate hydrochloride was given with only a change in the consistency and frequency of stools reported as well as three rashes, two cases of nausea and one case of dizziness.

Hemodialysis and peritoneal dialysis are not effective means of removing the compound from the blood.

The average biological half-life of clindamycin is 2.4 hours and is approximately two hours in pediatric patients.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
---

## ACTION AND CLINICAL PHARMACOLOGY

### Mechanism of Action

Clindamycin palmitate hydrochloride is a water soluble palmitic acid ester of clindamycin. The intact ester is essentially inactive as an antibacterial agent. Chemical or enzymatic hydrolysis of clindamycin palmitate hydrochloride is necessary to obtain the antibiotic activity of the clindamycin base. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. It binds to the 50S ribosomal subunit and affects both ribosome assembly and the translation process. At usual doses, clindamycin exhibits bacteriostatic activity *in vitro*.

### Pharmacodynamics

See **MICROBIOLOGY**.

### Pharmacokinetics

#### Absorption

Clindamycin is rapidly and almost completely (90%) absorbed from the gastrointestinal tract in man. Concomitant administration of food does not adversely affect the absorption of clindamycin released by the hydrolysis of clindamycin palmitate hydrochloride.

### Metabolism

Clindamycin palmitate hydrochloride is rapidly hydrolyzed to clindamycin in the intestinal tract. *In vitro* studies in human liver and intestinal microsomes indicate clindamycin is predominantly oxidized by CYP3A4, with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.

### Distribution

Clindamycin binds primarily to alpha-1-acid glycoprotein. Protein binding is concentration dependent, ranging from 60% to 94% at therapeutic serum concentrations.

Clindamycin is widely distributed in body fluids and tissues. Tissue levels of clindamycin have been determined in various tissues in adult patients undergoing surgical procedures as noted in Table 3.

Clindamycin does not cross the blood-brain-barrier even in the presence of inflamed meninges.

**TABLE 3**

<b>Specimen</b>	<b>No. of Specimens</b>	<b>Average Serum Level mcg/mL</b>	<b>Average Fluid Level mcg/mL</b>	<b>Tissue Level mcg/mL</b>
Pancreatic fluid	4	1.15	45.1	
Bile	19	3.35	52.45	
Gall Bladder	16	0.81		4.33
Liver	1	42.35		3.80
Kidney	1	1.50		9.07
Bone	2	2.44		9.91

### Excretion

Elimination of free clindamycin in the urine during a 24 hour period following a single dose of clindamycin palmitate hydrochloride was 9% of the administered drug and was similar to the percentage excreted by patients treated with clindamycin hydrochloride.

The average elimination half-life is 2.4 hours. After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4 –5.1 h) in the elderly compared to 3.2 hours (range 2.1 - 4.2 h) in younger adults.

### **Special Populations and Conditions**

**Geriatrics:** Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.

**Pediatrics:** Serum level studies with clindamycin palmitate hydrochloride in children weighing 50-100 lbs given 2, 3 and 4 mg/kg every 6 hours (8, 12, or 16 mg/kg/day) demonstrated mean one hour serum levels of clindamycin after the first dose (peak levels observed in this study) of 1.24, 2.25, and 2.44 mcg/mL respectively. There was no indication of drug accumulation. By the fifth dose the 6-hour serum concentration had reached equilibrium, indicating that the peak serum concentrations after this time would be about what they were on Day 4, namely, 0.72, 1.23 and 1.45 mcg/mL with doses of 8, 12 or 16 mg/kg/day, respectively. Serum levels have been uniform and predictable from patient to patient and dose to dose.

The biological half-life of clindamycin after doses of clindamycin palmitate hydrochloride is approximately 2 hours in children.

Multiple dose studies in newborn and infants up to 6 months of age showed that the drug did not accumulate in the serum and was excreted rapidly. Two out of five patients did have higher serum levels, the significance of which is not clear.

## **STORAGE AND STABILITY**

Before reconstitution, store at controlled room temperature (20-25°C).

Do not refrigerate the reconstituted solution, since under conditions of low temperature, the solution may thicken and is difficult to pour.

The reconstituted solution is stable at room temperature for 14 days.

## **SPECIAL HANDLING INSTRUCTIONS**

There are no special handling instructions.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

Each 100mL glass bottle of DALACIN C FLAVOURED GRANULES (clindamycin palmitate hydrochloride) contains clindamycin palmitate hydrochloride equivalent to 1500 mg of clindamycin base.

Nonmedicinal ingredients: artificial cherry flavour, ethyl paraben, pluronic F68, polymethylsiloxane, sucrose. Energy: 25.1 kj (6 kcal)/5mL. Sodium: trace. Gluten-free.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper Name: clindamycin palmitate hydrochloride

Chemical Name:

L-threo- $\alpha$ -D-galacto-Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-,2-hexadecanoate, monohydrochloride, (2S-trans)- or 7(S)-chloro-7-deoxylincomycin 2-palmitate, hydrochloride.

Structural Formula:



Molecular Formula:  $C_{34}H_{63}ClN_2O_6S.HCl$

Molecular Weight: 699.86

Description: Clindamycin palmitate hydrochloride is a water-soluble hydrochloride salt of the ester of clindamycin and palmitic acid and is a white to off-white amorphous powder with a characteristic odour. It is very soluble in DMF (N,N-dimethylformamide), freely soluble in water, chloroform and ether, and soluble in alcohol and ethyl acetate. A 1% solution in water has a pH of 2.8 to 3.8.

## CLINICAL TRIALS

The authorized indications were based on safety and efficacy clinical trials which were conducted with DALACIN C FLAVOURED GRANULES.

## DETAILED PHARMACOLOGY

Serum level studies with a 150 mg oral dose of clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. An average peak serum level of 2.50 mcg/mL was reached in 45 minutes; serum levels averaged 1.51 mcg/mL at 3 hours and 0.70 mcg/mL at 6 hours. Absorption of an oral dose is virtually complete (90%), and the concomitant administration of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Serum level studies following multiple doses of clindamycin hydrochloride for up to 14 days show no evidence of accumulation or altered metabolism of drug. Clindamycin palmitate hydrochloride was detected in serum at less than 0.35 mcg/mL following a 300 mg dose of this salt. Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Concentrations of clindamycin in the serum increased linearly with increased dose. Serum levels exceed the MIC (minimum inhibitory concentration) for most indicated organisms for at least six hours following administration of the usually recommended doses. Clindamycin is widely distributed in body fluids and tissues (including bones). The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Doses of up to 2 grams of clindamycin per day for 14 days have been well tolerated by healthy volunteers, except that the incidence of gastrointestinal side effects is greater with the higher doses. No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges. Pharmacokinetic studies in elderly volunteers (61-79 years) and younger adults (18-39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4 –5.1 h) in the elderly compared to 3.2 hours (range 2.1 - 4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function.

## MICROBIOLOGY

Efficacy is related to the time period over which the agent level is above the minimum inhibitory concentration (MIC) of the pathogen (%T/MIC).

### Resistance

Resistance to clindamycin is most often due to mutations at the rRNA antibiotic binding site or methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit. These

alterations can determine *in vitro* cross resistance to macrolides and streptogramins B (MLS<sub>B</sub> phenotype). Resistance is occasionally due to alterations in ribosomal proteins. Resistance to clindamycin may be inducible by macrolides in macrolide-resistant bacterial isolates. Inducible resistance can be demonstrated with a disk test (D-zone test) or in broth. Less frequently encountered resistance mechanisms involve modification of the antibiotic and active efflux. There is complete cross resistance between clindamycin and lincomycin. As with many antibiotics, the incidence of resistance varies with the bacterial species and the geographical area. The incidence of resistance to clindamycin is higher among methicillin-resistant staphylococcal isolates and penicillin-resistant pneumococcal isolates than among organisms susceptible to these agents.

### Breakpoints

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Particularly in severe infections or therapy failure microbiological diagnosis with verification of the pathogen and its susceptibility to clindamycin is recommended.

Resistance is usually defined by susceptibility interpretive criteria (breakpoints) established by Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing (EUCAST) for systemically administered antibiotics.

In order to assess the significance of *in vitro* antibiotic activity against bacterial species, it is necessary to compare the organism's minimum inhibitory concentration (MIC) to the defined susceptibility interpretive breakpoints for the antibiotic. **Table 4** identifies the currently-accepted MIC interpretative breakpoints for clindamycin.

The *in vitro* activity of clindamycin in combination with primaquine has not been determined.

Clinical and Laboratory Standards Institute (CLSI) breakpoints for relevant organisms are listed below.

**Table 4. CLSI Susceptibility Interpretive Criteria for Clindamycin**

Pathogen	Minimal Inhibitory Concentrations (MIC in mcg/mL)			Disk Diffusion (Zone Diameters in mm) <sup>a</sup>		
	S	I	R	S	I	R
<i>Staphylococcus</i> spp.	≤ 0.5	1–2	≥ 4	≥ 21	15–20	≤ 14
<i>Streptococcus pneumoniae</i> and other <i>Streptococcus</i> spp.	≤ 0.25	0.5	≥ 1	≥ 19	16–18	≤ 15
Anaerobic Bacteria <sup>b</sup>	≤ 2	4	≥ 8	NA	NA	NA

NA = not applicable

<sup>a</sup>Disk content 2 micrograms of clindamycin

<sup>b</sup>MIC ranges for anaerobes are based on agar dilution methodology

A report of “Susceptible” (S) indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” (R) indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the usually achievable concentrations; other therapy should be selected.

The reported clindamycin MIC<sub>90</sub> value (i.e., the concentration of clindamycin that inhibits 90% of test isolates) was utilized as the most descriptive measure of clindamycin activity. Where the data from more than one study are summarized, the weighted average MIC<sub>90</sub> value was calculated to account for differences in the number of strains in each study.

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard clindamycin powder should provide the MIC ranges in Table 5. For the disk diffusion technique using the 2 mcg clindamycin disk the criteria provided in Table 5 should be achieved.

**Table 5. CLSI Acceptable Quality Control (QC) Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results**

QC Strain	Minimum Inhibitory Concentration Range (mcg/mL)	Disk Diffusion Range (Zone Diameters in mm)
<i>Staphylococcus aureus</i> ATCC 29213	0.06–0.25	NA
<i>Staphylococcus aureus</i> ATCC 25923	NA	24–30
<i>Streptococcus pneumoniae</i> ATCC 49619	0.03–0.12	19–25
<i>Bacteroides fragilis</i> ATCC 25285	0.5–2 <sup>a</sup>	NA
<i>Bacteroides thetaiotaomicron</i> ATCC 29741	2–8 <sup>a</sup>	NA
<i>Eggerthella lenta</i> ATCC 43055	0.06–0.25 <sup>a</sup>	NA

NA=Not applicable.

ATCC<sup>®</sup> is a registered trademark of the American Type Culture Collection

<sup>a</sup>MIC ranges for anaerobes are based on agar dilution methodology.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints are presented below.

**Table 6. EUCAST Susceptibility Interpretive Criteria for Clindamycin**

Organism	MIC breakpoints (mg/L)		Zone diameter breakpoints (mm) <sup>a</sup>	
	S ≤	R >	S ≥	R <
<i>Staphylococcus</i> spp.	0.25	0.5	22	19
<i>Streptococcus</i> Groups A, B, C and G	0.5	0.5	17	17
<i>Streptococcus pneumoniae</i>	0.5	0.5	19	19
<i>Viridans group streptococci</i>	0.5	0.5	19	19
Gram-positive anaerobes	4	4	NA	NA
Gram-negative anaerobes	4	4	NA	NA
<i>Corynebacterium</i> spp.	0.5	0.5	20	20

<sup>a</sup>Disk content 2 µg of clindamycin  
NA=not applicable; S=susceptible; R=resistant

EUCAST QC ranges for MIC and disk zone determinations are in the table below.

**Table 7. EUCAST Acceptable Quality Control (QC) Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results**

QC Strain	Minimum Inhibitory Concentration Range (mcg/mL)	Disk Diffusion Range (Zone Diameters in mm)
<i>Staphylococcus aureus</i> ATCC 29213	0.06–0.25	23-29
<i>Streptococcus pneumoniae</i> ATCC 49619	0.03–0.125	22-28

ATCC® is a registered trademark of the American Type Culture Collection

The *in vitro* susceptibility of clinical isolates to clindamycin is presented in **Table 8** (gram-positive aerobic bacteria), **Table 9** (gram-negative aerobic bacteria), **Table 10** (gram-positive anaerobic bacteria), **Table 11** (gram-negative anaerobic bacteria) and **Table 12** (*Chlamydia* spp and *Mycoplasma* spp).

Organism	N <sup>b</sup>	MIC <sub>90</sub> Range <sup>c</sup>	MIC <sub>90</sub> <sup>d</sup>
<i>Bacillus cereus</i>	46	1	1
<i>Corynebacterium diphtheriae</i>	192	0.1	0.1
<i>Listeria monocytogenes</i>	218	1-8	2.22
<i>Staphylococcus aureus</i> (methicillin-susceptible)	286	0.12-2	0.50
<i>Staphylococcus saprophyticus</i>	57	0.12-0.25	0.16
<i>Streptococcus agalactia</i>	59	≤0.06-0.50	0.15
<i>Streptococcus bovis</i>	22	0.04	0.04
<i>Streptococcus pneumoniae</i> (penicillin-susceptible)	660	0.03-0.25	0.23
<i>Streptococcus pyogenes</i>	141	0.13-0.25	0.08
<i>Streptococcus</i> spp, Group B	38	≤0.12-0.25	0.15
<i>Streptococcus</i> spp, Group C	30	≤0.12-0.50	0.22
<i>Streptococcus</i> spp, Group G	34	0.06-0.50	0.31
<i>Streptococcus</i> spp, viridans Group (penicillin-susceptible)	67	≤0.06-1.6	0.53

<sup>a</sup> clinical efficacy has not been established for some of these species

<sup>b</sup> N, total number of isolates

<sup>c</sup> Range of reported MIC<sub>90</sub> values

<sup>d</sup> MIC<sub>90</sub> for single study or weighted average MIC<sub>90</sub> for two or more studies

<b>Table 9: <i>In vitro</i> activity of clindamycin against gram-negative aerobic bacteria<sup>a</sup></b>			
<b>Organism</b>	<b>N<sup>b</sup></b>	<b>MIC<sub>90</sub> Range<sup>c</sup></b>	<b>MIC<sub>90</sub><sup>d</sup></b>
<i>Campylobacter jejuni</i>	449	0.39-8	1.7
<i>Campylobacter fetus</i>	41	1-1.6	1.2
<i>Campylobacter coli</i>	31	0.50	0.50
<i>Gardnerella vaginalis</i>	156	≤0.06-0.39	0.3
<i>Helicobacter pylori</i>	47	2-3.1	2.6
<i>Neisseria gonorrhoeae</i> (β-lactamase-negative)	77	4	4
<i>Neisseria gonorrhoeae</i> (β-lactamase-positive)	54	2	2

<sup>a</sup> clinical efficacy has not been established for some of these species

<sup>b</sup> N, total number of isolates

<sup>c</sup> Range of reported MIC<sub>90</sub> values

<sup>d</sup> MIC<sub>90</sub> for single study or weighted average MIC<sub>90</sub> for two or more studies

<b>Table 10: <i>In vitro</i> activity of clindamycin against gram-positive anaerobic bacteria<sup>a</sup></b>			
<b>Organism</b>	<b>N<sup>b</sup></b>	<b>MIC<sub>90</sub> Range<sup>c</sup></b>	<b>MIC<sub>90</sub><sup>d</sup></b>
<i>Actinomyces israelii</i>	46	0.12	0.12
<i>Actinomyces</i> spp	38	0.50-1	0.8
<i>Clostridium botulinum</i>	224	4	4
<i>Clostridium difficile</i>	191	4->256	57.7
<i>Clostridium novyi</i>	18	2	2
<i>Clostridium perfringens</i>	386	0.25-8	3.4
<i>Clostridium ramosum</i>	98	4-12.5	8.3
<i>Eubacterium</i> spp	45	0.4-2	1.1
<i>Lactobacillus</i> spp	88	0.50-1	0.8
<i>Peptostreptococcus anaerobes</i>	283	0.25-0.50	0.4
<i>Peptostreptococcus asaccharolyticus</i>	268	0.25-2	1.5
<i>Peptostreptococcus magnus</i>	90	2	2
<i>Peptostreptococcus prevotii</i>	87	0.12-4	2.9
<i>Peptostreptococcus tetradius</i>	28	0.5	0.5
Anaerobic gram-positive cocci	247	0.5-1	0.9
<i>Propionibacterium acnes</i>	267	0.10-0.25	0.2
<i>Propionibacterium</i> spp	71	0.12-0.20	0.16

<sup>a</sup> clinical efficacy has not been established for some of these species

<sup>b</sup> N, total number of isolates

<sup>c</sup> Range of reported MIC<sub>90</sub> values

<sup>d</sup> MIC<sub>90</sub> for single study or weighted average MIC<sub>90</sub> for two or more studies

Organism	N <sup>b</sup>	MIC <sub>90</sub> Range <sup>c</sup>	MIC <sub>90</sub> <sup>d</sup>
<i>Bacteroides fragilis</i> group	4,284	0.5-8	2.45
<i>Bacteroides fragilis</i>	2,002	≤0.20-4	2.22
<i>Bacteroides melaninogenicus</i>	224	≤0.03-0.50	0.07
<i>Bacteroides</i> spp	141	≤0.06-0.50	0.31
<i>Bacteroides bivius</i>	155	≤0.03-≤0.05-	≤0.11
<i>Bacteroides disiens</i>	33	≤0.03-≤0.06	≤0.05
<i>Fusobacterium</i> spp	330	≤0.10-2	0.85
<i>Mobiluncus mulieris</i>	10	0.06	0.06
<i>Mobiluncus curtisii</i>	12	0.12	0.12
<i>Veillonella</i> spp	38	0.06-0.25	0.20

<sup>a</sup> clinical efficacy has not been established for some of these species

<sup>b</sup> N, total number of isolates

<sup>c</sup> Range of reported MIC<sub>90</sub> values

<sup>d</sup> MIC<sub>90</sub> for single study or weighted average MIC<sub>90</sub> for two or more studies

Clindamycin has demonstrated *in vitro* activity against *Chlamydia trachomatis* and *Mycoplasma* spp (see **Table 12**). For *Chlamydia trachomatis*, the MIC<sub>90</sub> for clindamycin is reached at 2.3 µg/mL; *in vitro* synergism with gentamicin has also been demonstrated.

Organism	N <sup>b</sup>	MIC <sub>90</sub> Range <sup>c</sup>	MIC <sub>90</sub> <sup>d</sup>
<i>Chlamydia trachomatis</i>	84	0.5-5.9	2.3
<i>Mycoplasma hominis</i>	106	0.25-0.8	0.58
<i>Mycoplasma pneumoniae</i>	9	4	4

<sup>a</sup> clinical efficacy has not been established for some of these species

<sup>b</sup> N, total number of isolates

<sup>c</sup> Range of reported MIC<sub>90</sub> values

<sup>d</sup> MIC<sub>90</sub> for single study or weighted average MIC<sub>90</sub> for two or more studies

Development of resistance to clindamycin by staphylococci is slow and stepwise rather than rapid and streptomycin-like. Clindamycin, like lincomycin, participates in the dissociated cross-resistance phenomenon with erythromycin. Clindamycin is not cross-resistant with penicillin, ampicillin, tetracycline or streptomycin. It is, however, cross-resistant with lincomycin.

Resistance to clindamycin may occur by one of several mechanisms. Resistance does not appear to be caused by reduced drug uptake but rather is generally due to alterations in the bacterial

target site (50S ribosomal subunit). Resistance can result from either changes in a ribosomal protein at the receptor site or a change in the 23S ribosomal RNA by methylation of adenine. Rare isolates of staphylococci and some veterinary isolates of streptococci may enzymatically inactivate clindamycin by adenylation. Plasmid-mediated transferable resistance to clindamycin (and erythromycin) in *B. fragilis* was reported in 1979. Despite the existence of multiple resistance mechanisms, the reported incidence of clindamycin resistance in the *B. fragilis* group has remained relatively low (averaging 5.3% from 1970-1987 in over 7,600 isolates). Susceptibility of isolates to clindamycin should be assessed by individual MIC determination.

## TOXICOLOGY

### **Human: Special Tolerance Studies**

Two multiple dose studies were performed in children and one multiple dose study was performed in adults.

One group of 52 children received 17 doses of clindamycin palmitate hydrochloride as follows:

<b>Weight (or Age)</b>	<b>Number of Children</b>	<b>Dose (mg/kg/day)</b>
Group 1: 50-100 lbs	11	8
Group 2: 50-100 lbs	11	12
Group 3: 50-100 lbs	10	16
Group 4: 30-50 lbs	13	8
Group 5: 6 mos-2 yrs.	7	8

Serum antibiotic levels and complete clinical laboratory determinations were done. There were no clinical or laboratory indications that the 17 dose course in the recommended dosage range (8 to 16 mg/kg/day) causes toxicity to the hematopoietic, renal, hepatic or central nervous systems.

A second group of 13 infants under the age of 6 months was treated with doses of 12 to 16 mg/kg/day for various infections. In one patient with Down's Syndrome suffering from an upper respiratory and urinary tract infection, the SGPT rose from 90 to 150 units and the serum bilirubin rose from 0.2 to 1.8 mg/mL.

An adult multiple-dose tolerance study was performed in a group of 210 men dosed as follows for 21 days:

Group I:	52 subjects	300 mg	(20 cc)	every 8 hours
Group II:	54 subjects	20 cc	placebo	every 8 hours
Group III:	53 subjects	600 mg	(40 cc)	every 8 hours
Group IV:	51 subjects	40 cc	placebo	every 8 hours

Complete clinical laboratory testing was performed and no evidence was found to indicate that clindamycin palmitate hydrochloride caused toxic changes in the hematopoietic system, kidneys or liver.

### **Animal**

The results of acute toxicity studies in animals are shown in Table 13.

**TABLE 13**

<b>Species</b>	<b>Route</b>	<b>LD<sub>50</sub> (mg/kg)</b>
Adult mouse	IP	> 2500
Adult rat	Oral	> 5000
Adult rat	IP	> 2500
Adult rat	SC	> 2000
Newborn rat	SC	> 1250

The following subacute and chronic animal toxicology was performed.

#### **7 Day Oral Tolerance Study in Rats**

1000 mg/kg was administered to rats with no drug related toxicity noted except some increase in body weight in females.

#### **7 Day Oral Tolerance Study in the Dog**

A dose of 600 mg/kg was administered. Leucocyte values fluctuated somewhat during the pre-test and treatment periods. There was a relative decrease in neutrophils. Alkaline phosphatase values were elevated post treatment in 2 of 3 dogs but no morphologic effect of the drug was detected in the liver of these dogs.

#### **6 Month Chronic Oral Toxicity in the Rat**

Clindamycin palmitate hydrochloride, at doses of 100, 300 and 600 mg/kg was given to groups of 20 rats daily for 6 months. Data obtained after two months were normal. Similarly, data at the end of 6 months showed no drug related effects. Female body weight was greater in the treated groups than in the controls.

#### **6 Month Chronic Oral Toxicity in the Dog**

Dogs were administered clindamycin palmitate hydrochloride at doses of 0, 30, 100 and 300 mg/kg daily for 6 months, and all 3 treatment levels were well tolerated. Alkaline phosphatase levels were elevated in 3 dogs (2 controls, and one at 300 mg/kg) but no other abnormalities were noted.

### **Teratogenic and Reproductive Studies in the Rat and Rabbit**

Clindamycin palmitate hydrochloride was not teratogenic when given to pregnant rats from gestation day 6 through 15 at levels of 300 and 600 mg/kg/day. The reproductive performance of treated rats was comparable to control rats.

Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the fetus due to clindamycin, except at doses that caused maternal toxicity.

In oral embryo fetal development studies in rats and subcutaneous embryo fetal development studies in rats and rabbits, no developmental toxicity was observed except at doses that produced maternal toxicity.

### **Carcinogenesis**

Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential.

### **Mutagenesis**

Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative.

## REFERENCES

1. Bartlett JG, Onderdonk, AB and Cisneros RL: Clindamycin-Associated Colitis in Hamsters: Protection with Vancomycin. *Gastroenterology* 1977;73:772-776.
2. Bartlett JG, Chang T, and Onderdonk AB: Comparison of Five Regimens for Treatment of Experimental Clindamycin-Associated Colitis. *J Infect Dis* 1978;138:81-86.
3. Bartlett JG, Chang T, Taylor NS and Onderdonk AB: Colitis Induced by *Clostridium difficile*. *Rev Infect Dis* 1979;1:370-378.
4. Browne RA, Fekety R, Silva J, Boyd DI, Work CO and Abrams GD: The Protective Effect of Vancomycin on Clindamycin-Induced Colitis in Hamsters. *Johns Hopkins Medical Journal* 1977;141:183-192.
5. Burdon DW, Brown JD, George RH, Arabi Y, Alexander-Williams J and Keighley MRB: Pseudo-membranous Colitis Caused by *Clostridia*. (Letter) *New England Journal of Medicine* 1978;299:48.
6. Burdon DW, Brown JD, Young DJ, Arabi Y, Shinagawa N, Alexander-Williams J and Keighley MRB: Antibiotic Susceptibility of *Clostridium difficile*. *J Antimicrob Chemother* 1979;5:307-310.
7. Fekety R: Prevention and Treatment of Antibiotic-Associated Colitis. *Microbiology - 1979:276-279*, American Society for Microbiology, Washington, D.C. 1979.
8. George WL, Kirby BD, Sutter VL and Finegold SM: Antimicrobial Susceptibility of *Clostridium difficile*. *Microbiology - 1979:267-271*, American Society for Microbiology, Washington, D.C. 1979.
9. Gordon RC, Regamey C, Kirby WMM: Serum protein binding of erythromycin, lincomycin, and clindamycin. *J Pharm Sci* 1973;62(7):1074-1076.
10. Humphrey CD, Condon CW, Cantey JR and Pittman FE: Partial Purification of a Toxin Found in Hamsters with Antibiotic-Associated Colitis: Reversible Binding of the Toxin by Cholestyramine. *Gastroenterology* 1978;74:1046.
11. Katz L, Lamont JT, Trier JS, Sonnenblick EB, Rothman SW, Broitman SA and Rieth J: Experimental Clindamycin-Associated Colitis in Rabbits: Evidence of Toxin-Mediated Mucosal Damage. *Gastroenterology* 1978;74:246-252.
12. Kays MB, White RL, Gatti G, Gambertoglio JG: Ex vivo protein binding of clindamycin in sera with normal and elevated alpha1-acid glycoprotein concentrations. *Pharmacotherapy* 1992;12(1):50-55.

13. Keighley MRB, Burdon DW, Arabi Y, Alexander-Williams J, Thompson H, Young D, Johnson M, Bentley S, George RH and Mogg GAG: Randomised Controlled Trial of Vancomycin for Pseudomembranous Colitis and Post-operative Diarrhoea. *British Medical Journal* 1978;2:1667-1669.
14. LaMont JT, Sonnenblick EB and Tothman S: Role of Clostridial Toxin in the Pathogenesis of Clindamycin Colitis in Rabbits. *Gastroenterology* 1979;76:356-361.
15. Lwin N and Collipp PJ: Absorption and Tolerance of Clindamycin-2-palmitate in infants below 6 months of age. *Current Therapeutic Research*. 1970;12:648-657.
16. Tedesco F, Markham R, Gurwith M, Christie D and Bartlett JG: Oral Vancomycin for Antibiotic-Associated Pseudomembranous Colitis. *Lancet* 1978;2:226-228.
17. Wynalda MA, Hutzler JM, Koets, MD, Podoll T, Wienkers LC: In vitro metabolism of clindamycin in human liver and intestinal microsomes. *Drug Meta Dispos* 2003;31:878-887.

## **PART III: PATIENT MEDICATION INFORMATION**

### **PrDALACIN<sup>®</sup> C FLAVOURED GRANULES** (Clindamycin Palmitate Hydrochloride for Oral Solution USP) 75 mg/5 mL clindamycin

**Read this carefully before you start taking DALACIN C FLAVOURED GRANULES and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about DALACIN C FLAVOURED GRANULES.**

**Antibacterial drugs like DALACIN C FLAVOURED GRANULES treat only bacterial infections. They do not treat viral infections such as the common cold. Although you may feel better early in treatment, DALACIN C FLAVOURED GRANULES should be taken exactly as directed. Misuse or overuse of DALACIN C FLAVOURED GRANULES could lead to the growth of bacteria that will not be killed by DALACIN C FLAVOURED GRANULES (resistance). This means that DALACIN C FLAVOURED GRANULES may not work for you in the future.**

#### **What DALACIN C FLAVOURED GRANULES is used for?**

**DALACIN C FLAVOURED GRANULES is used:**

- To treat serious infections caused by germs.
- To help prevent serious infections during and after surgery.

#### **How does DALACIN C FLAVOURED GRANULES work?**

DALACIN C FLAVOURED GRANULES prevents the growth of the germs (bacteria) responsible for your infection.

#### **What are the ingredients in DALACIN C FLAVOURED GRANULES?**

Medicinal ingredients: Clindamycin palmitate hydrochloride.

Non-medicinal ingredients: artificial cherry flavour, ethyl paraben, pluronic F68, polymethylsiloxane, sucrose (when reconstituted with 75 mL of water, each 5 mL contains approximately 1837 mg of sucrose). Energy: 25.1 kJ (6 kcal)/5mL. Sodium: trace. Gluten-free.

#### **DALACIN C FLAVOURED GRANULES comes in the following dosage forms:**

Oral Solution 100 ml size: 75 mg clindamycin / 5 mL when reconstituted.

#### **Do not use DALACIN C FLAVOURED GRANULES if:**

- You have a history of allergies (hypersensitive) to
  - Clindamycin
  - Lincomycin
  - Other ingredients in the product (see list of non-medicinal ingredients)

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DALACIN C FLAVOURED GRANULES. Talk about any health**

**conditions or problems you may have, including if you:**

- have had intestinal disorders such as:
  - colitis (inflammation of the colon).
  - inflammatory bowel disease.
- have diarrhea or get diarrhea when you take antibiotics.
- suffer from problems with your stomach or intestines (e.g. bowel disease, colitis).
- suffer from problems with your kidneys or liver.
- have glucose-6-dehydrogenase (G-6-PD) deficiency and are taking primaquine. You need to have routine blood tests while taking DALACIN C FLAVOURED GRANULES with primaquine to monitor for potential blood changes.
- are pregnant or planning to become pregnant. Clindamycin passes to the human fetus.
- are breastfeeding or planning to breastfeed.

**Other warnings you should know about:**

The medicine contains sucrose, so it is important to have good oral hygiene. Brush your teeth twice daily with toothpaste.

**Breastfeeding**

If you are breastfeeding or planning to breastfeed while taking DALACIN C FLAVOURED GRANULES, talk to your doctor. DALACIN C FLAVOURED GRANULES will pass through your breast milk to your baby. Your doctor will decide if you should take this medicine while breastfeeding. If your doctor has told you that you can take DALACIN C FLAVOURED GRANULES while breastfeeding, monitor your baby for possible side effects such as: diarrhea, mouth infection (thrush: white lesions in your baby's mouth), diaper rash or blood in their stool. If your baby shows any signs, talk to your doctor and to your baby's doctor.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with DALACIN C FLAVOURED GRANULES:**

- Erythromycin (an antibiotic)
- Rifampin (an antibiotic)
- Muscle relaxants used for operations
- Aminoglycosides (a class of antibiotics)
- Primaquine (antimalarial)
- St-John's wort (*Hypericum perforatum*)

Tell your doctor if you are taking or being administered any other topical or oral medication, including neuromuscular blocking agents.

**How to take DALACIN C FLAVOURED GRANULES:**

Take your medicine (or give the medicine to your child) as your doctor has told you. If you are not sure, ask your doctor or pharmacist.

**Usual dose:**

Treatment of infection:

**Child dose (over 1 month of age):**

The daily dose is based on the body weight and the severity of the infection.

The daily dose is to be given to the child in divided doses every 8 hours or 6 hours.

Keep taking this medicine for the full time of treatment, even if you (or your child) begin to feel better after a few days.

Prevention of infection (patients undergoing surgery):

**Adult dose:**

300 mg by mouth at 1 hour before procedure; then 150 mg at 6 hours after the first dose.

**Child dose (over 1 month of age):**

10 mg per kg by mouth at 1 hour before procedure; then 5 mg/kg at 6 hours after the first dose.

The medication can be taken with or without food.

**Overdose:**

If you think you have taken too much DALACIN C FLAVOURED GRANULES, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**Missed Dose:**

If you missed a dose of this medication, take it as soon as you remember. This will help to keep a constant amount of medication in your blood. But, if it is almost time for your next dose, skip the missed dose and continue with your next scheduled dose. Do not take two doses at the same time.

**What are possible side effects from using DALACIN C FLAVOURED GRANULES?**

DALACIN C FLAVOURED GRANULES can cause side effects such as:

- skin reddening, rash, itching, hives
- feeling sick, vomiting, diarrhea, stomach pain
- sore throat, throat sores
- low red blood cells (anemia) with symptoms such as bruising, bleeding
- low white blood cells (neutropenia) which can lead to more infections
- vaginal infection or vaginitis (inflamed vagina)

Contact your doctor immediately if the following happens:

- You have a severe allergic reaction with symptoms such as:
  - swelling of the lips, throat, face or eyelids
  - difficulty breathing
  - rash, itching, blistering and peeling skin
- You have *Clostridium difficile colitis* (bowel inflammation) with symptoms such as:

- severe, persistent watery or bloody diarrhea (watery or bloody) with or without
  - abdominal pain
  - nausea
  - fever
  - vomiting.

This may happen months after the last dose of medication. If this occurs, stop taking and contact your doctor right away.

- You have liver problems with symptoms such as:
  - yellowing of the skin or eyes
  - abdominal pain, nausea, vomiting

<b>Serious side effects and what to do about them</b>			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>VERY COMMON</b> <b>Liver problems</b> with symptoms such a yellowing skin or eyes, abdominal pain, nausea, vomiting		√	√
<b>COMMON</b> Diarrhea Rash		√ √	
<b>RARE</b> Skin reactions: itching	√		
<b>NOT KNOWN</b> <b>Serious allergic (hypersensitivity) reaction</b> with symptoms such as swelling of eyes, mouth, throat, difficulty breathing, blistering or peeling skin, rash, itching			√
<b>Clostridium difficile associated disease</b> (bowel inflammation), with symptoms such as persistent or severe diarrhea, abdominal pain, nausea and vomiting			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your health care professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

Before reconstitution, store at controlled room temperature (20-25°C).

Do not refrigerate the reconstituted solution, since under conditions of low temperature, the solution may thicken and is difficult to pour.

The reconstituted solution is stable at room temperature for 14 days.

Keep out of the reach and sight of children.

### **If you want more information about DALACIN C FLAVOURED GRANULES:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website <https://www.canada.ca/en/health-canada.html>, the manufacturer's website (<http://www.pfizer.ca>), or by calling Pfizer Canada ULC at 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC

Last revised: 12 August 2019